BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VSV-IFNβ-NIS readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of VSV-IFNβ-NIS\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03017820-2802@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:VSV-IFNβ-NIS: Phase 1 readout est. (NCT03017820)
DESCRIPTION:VSV-IFNβ-NIS\, phase 1.\nStudy: A Vaccine (VSV-hIFNβ-NIS) Wit
 h or Without Cyclophosphamide and Combinations of Ipilimumab\, Nivolumab\,
  and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma\, Acut
 e Myeloid Leukemia or Lymphoma\nEstimated primary completion: 31 December 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/vsv-ifn-nis#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0301782
 0
URL:https://assetmemo.bio/drug/vsv-ifn-nis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508463-2802@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:VSV-IFNβ-NIS: Phase 1 readout est. (NCT06508463)
DESCRIPTION:VSV-IFNβ-NIS\, phase 1.\nStudy: Intravenous Vesicular Stomatit
 is Virus in Patients With Peripheral T-cell Lymphoma\nEstimated primary co
 mpletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/vsv-ifn-nis#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06508463
URL:https://assetmemo.bio/drug/vsv-ifn-nis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2802@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:VSV-IFNβ-NIS: Phase 2 readout est. (NCT01042379)
DESCRIPTION:VSV-IFNβ-NIS\, phase 2.\nStudy: I-SPY TRIAL: Neoadjuvant and P
 ersonalized Adaptive Novel Agents to Treat Breast Cancer\nEstimated primar
 y completion: December 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/vsv-ifn-nis#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/vsv-ifn-nis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07510334-2802@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:VSV-IFNβ-NIS: Phase 2 readout est. (NCT07510334)
DESCRIPTION:VSV-IFNβ-NIS\, phase 2.\nStudy: VSV-IFNβ-NIS With Ipilimumab 
 and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal
  Cell Carcinoma\nEstimated primary completion: 1 August 2033. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vsv-ifn-nis#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07510334
URL:https://assetmemo.bio/drug/vsv-ifn-nis#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
